AMC Entertainment heads into the back half of August with a stock that has rallied 23% over the past month yet slipped back slightly this week, while short sellers quietly rebuild positions and options traders turn more cautious than they have been all year.
The most striking tension in the data is the divergence between the monthly price surge and what shorts are doing right now. SI climbed 4.5% over the past week to 9.2% of the free float — roughly 47 million shares — reversing a longer unwind that had cut short positions by nearly 10% over the prior month. That month-long cover trade tracked directly with the stock's move from under $2 to $2.38. The weekly rebuild suggests some bears view the rally as an opportunity to re-enter, not a reason to stay out. Crucially though, the borrow market is not under pressure. Availability runs at 880% — meaning shares available to borrow dwarf the current short position by almost nine to one — and cost to borrow is just 0.70%, its highest level in a month but still firmly low by any standard. There is no mechanical squeeze pressure here.
Options positioning has quietly drifted more defensive over the past month. The put/call ratio hit 0.259 on Tuesday — not extreme in isolation, but now running about 1.2 standard deviations above its 20-day average of 0.243 and close to its 52-week high of 0.273. The consistent drift higher in the PCR since late July, when it was printing near 0.18, suggests options participants have added downside protection as the stock moved up. That kind of hedging is consistent with a market that believes in the move but is not willing to ride it unprotected.
The Street's reaction to AMC's most recent results — Q2 reported August 4 — tells a clear story. The stock fell 6% the day after and dropped a further 16% over the following five trading sessions. That contrasts sharply with the July 20 event, which appears to reflect a separate corporate development that sent the stock up 13% on the day and 29% over the subsequent week. Analyst activity around the July events was broadly constructive: multiple firms raised targets following the July catalyst, with Wedbush lifting to $4.00 and Benchmark moving to $3.00, though both B. Riley and Macquarie stayed Neutral with more modest targets around $2.50. The mean Street target of $2.72 sits only modestly above the current $2.38 price, leaving limited implied upside on consensus. Citigroup retains a Sell rating with a $1.20 target — a significant outlier that anchors the bearish camp.
The fundamental debate remains unresolved. Bulls point to EBITDA growth projections of 53% for 2026, margin expansion from 8% toward 12% by 2027, and a strong blockbuster film slate. Bears flag persistent net losses, with adjusted EBITDA still in negative territory and net leverage at 9.3x — even if the trajectory toward 7x by year-end is the right direction. Institutional ownership adds an interesting wrinkle: Marshall Wace disclosed a near-fresh position of 30.4 million shares as of June 30, representing almost the entire position as a new holding. BlackRock also added 16.2 million shares in the most recent reported period. Both moves suggest institutional interest is growing even as the fundamental story remains contested.
The next scheduled earnings print is November 6. Between now and then, the weekly pattern in short interest — whether bears continue to rebuild or reverse again — alongside whether the PCR drift toward its 52-week high continues, will be the clearest read on how the market is leaning into what has been a remarkably volatile year for the stock.
See the live data behind this article on ORTEX.
Open AMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
